The primary mission of the Center for Movement Disorders is to provide advanced state-of-the-art neurosurgical treatments for patients with disabling neurological disorders.
The Center for Movement Disorder Surgery was established in 1998 as a collaboration between the Departments of Neurology and Neurological Surgery of Columbia University. Our primary mission is to provide advanced state-of-the-art neurosurgical treatments for patients with disabling neurological disorders such as Parkinson’s disease, essential tremor, and dystonia, among others.
The decision to undergo surgery for Parkinson’s disease or other movement disorders is reached only after much deliberation. Patients with mild symptoms should not have this surgery. However, when conventional medical treatment has proved inadequate to control disabling symptoms, neurosurgical techniques such as deep brain stimulation may be an option.
To meet the growing demand for state-of-the art care for patients with movement disorders, we have brought together personnel and resources to create a comprehensive movement disorder surgery program. In the process, we have become one of the busiest and most experienced centers for deep brain stimulation techniques in the United States. Our surgeons perform approximately 50 deep brain stimulation implantations annually, and our clinical experience to date exceeds 400 patients.
The Center for Movement Disorder Surgery provides complete care to all patients through every stage of the surgical procedures, from patient education and pre-operative screening, to intra-operative brain mapping and surgery, to careful post-operative care and stimulator adjustments.
For more information, visit the Center for Movement Disorder Surgery at the Neurological Institute of New York.
Center for Movement Disorders Team
- [Disparities in access to deep brain stimulation surgery for Parkinson disease: interaction between African American race and Medicaid use].
- Features and timing of the response of single neurons to novelty in the substantia nigra.
- Unchanged safety outcomes in deep brain stimulation surgery for Parkinson disease despite a decentralization of care.
- Typical variations of subthalamic electrode location do not predict limb motor function improvement in Parkinson's disease.
- Staged bilateral thalamic electrode implantation utilizing frameless stereotactic guidance.
- A technique for minimally altering anatomically based subthalamic electrode targeting by microelectrode recording.
- Microelectrode recording-determined subthalamic nucleus length not predictive of stimulation-induced side effects.
- Subthalamic stimulation for Parkinson disease: determination of electrode location necessary for clinical efficacy.
- Implantation of bilateral deep brain stimulators in patients with Parkinson disease and preexisting cardiac pacemakers. Report of two cases.
The U.S. Food and Drug Administration (FDA) has just approved the Neuropace RNS Stimulator, an implantable device shown to reduce the frequency of seizures in epilepsy patients. The device is comprised of a small neurostimulator that is implanted in the skull under the skin and two electrodes placed on or near the part of the brain where the patient's seizures arise...